

Cystic fibrosis: Meveol effective against *Burkholderia dolosa*

The new generation of antimicrobial confirmed its potential with the evidence of effectiveness on this resistant bacterium kindly provided by Harvard Children's Hospital for which no therapeutic solution is available to date.

Lyon April 5th, 2011. Alaxia, a Lyons biotech that is developing the candidate drug Meveol hired an independent certified laboratory to confirm *in vitro* efficacy recorded by its microbiologists. The effect of Meveol has been studied on several strains of *Burkholderia dolosa*. Meveol bactericidal efficacy - over 99.9% - is observed in a few hours.

These results were obtained as part of a research partnership with Harvard Children's Hospital, Boston (USA), as *Burkholderia dolosa* affects their cystic fibrosis patients. This highly pathogen strain for CF patients is resistant to all known antibiotics.

Directly exiting Alaxia peroxidase platform, Meveol has already shown its effectiveness on many bacteria (+Gram, -Gram): eg mucoïd *Pseudomonas aeruginosa*, MRSA, *Mycobacterium abscessus*, *Burkholderia cepacia*. ... even on biofilm form.

"The effectiveness demonstrated over a superbacteria further confirms that the drug candidate Meveol opens a new therapeutic approach, particularly towards antibiotic-resistant bacteria, and this well beyond cystic fibrosis" said Philippe Bordeau, Alaxia CEO.

Alaxia focuses its efforts primarily on the inhaled form of the drug for cystic fibrosis application, and plans to finalize a new financial round in 2011 to accelerate development and to develop its own pipeline (URTI, LRTI, COPD, ...)

Part of these results will be presented during the conference "Progress in Antimicrobial Therapies" at the congress of the European Society of Cystic Fibrosis (ECFS), in Hamburg in June.

For more information contact: Phil Nussbaumer +33 6 13 95 36 57,
www.alaxia-pharma.eu

Meveol

The OSCN / Lactoferrin, developed under the name of Meveol, was designated orphan drug for cystic fibrosis in Europe and the United States.

Meveol:

- Is effective across a wide spectrum of bacteria, including multiresistant ones or gathered in biofilm.
- Presents no risk of antibiotic resistance
- Uses compounds present in the healthy lung, at physiological doses.
- Has a direct action by inhalation